白宫冠状病毒特别工作组成员布雷特·吉罗伊尔少将周日在美国全国广播公司上说,不建议使用羟氯喹作为Covid-19的治疗方法。

lindamy

时代广场舞照跳
VIP
注册
2005-11-23
消息
13,832
荣誉分数
3,021
声望点数
373
  • 3 min ago
    Hydroxychloroquine is not recommended as a Covid-19 treatment, coronavirus testing czar says
    From CNN's Naomi Thomas

    Hydroxychloroquine is not recommended as a treatment for Covid-19, Adm. Brett Giroir, a member of the White House coronavirus task force said on NBC on Sunday.
    “At this point in time, there’s been five randomized controlled, placebo controlled trials, that do not show any benefit to hydroxychloroquine,” Giroir said. “So, at this point in time, we don’t recommend that as a treatment.”
    Giroir said that hydroxychloroquine needs to be prescribed by a physician, and there may be circumstances where it is prescribed, in response to a question about the potentially mixed messages that are being sent out about the drug.

    “But I think most physicians and prescribers are evidence based and they’re not influenced by whatever is on Twitter or anything else,” he said. “And the evidence just doesn’t show that hydroxychloroquine is effective right now.”

    Giroir said that he thinks “we need to move on from that and talk about what is effective.”

    This includes public health measures like hand washing and mask wearing, and therapeutics and treatments that are known to be effective.

    “We have many things that do work,” Giroir said. “Right now, hydroxychloroquine, I can’t recommend that."

    More details: Giroir said that there were other therapeutics which have shown promise, such as remdesivir and steroids which have reduced mortality. He also said that while they still don’t know about immune plasma, there are trials and it has worked in other cases.
     

    lindamy

    时代广场舞照跳
    VIP
    注册
    2005-11-23
    消息
    13,832
    荣誉分数
    3,021
    声望点数
    373
    Here's Why Hydroxychloroquine Doesn't Block The Coronavirus in Human Lung Cells

    KATHERINE SELEY-RADTKE, THE CONVERSATION
    1 AUGUST 2020

    A paper came out in Nature on July 22 that further underscores earlier studies that show that neither the malaria drug hydroxychloroquine nor chloroquine prevents SARS-CoV-2 – the virus that causes COVID-19 – from replicating in lung cells.

    Most Americans probably remember that hydroxychloroquine became the focus of numerous clinical trials following the president's statement that it could be a "game changer." At the time, he appeared to base this statement on anecdotal stories, as well as a few early and very limited studies that hydroxychloroquine seemed to help patients with COVID-19 recover.

    Many in the antiviral field, including myself, questioned the validity of both, and in fact, one of the papers was later disparaged by the scientific society and the editor of the journal that published it.

    Since then, HQC has had a bumpy ride. It was initially approved by the FDA for emergency use. The FDA then quickly reversed its decision when numerous reports of deaths caused by heart arrhythmias emerged. That news brought many clinical trials to a halt.

    Regardless, some scientists continued to study it in hopes of finding a cure for this deadly virus.

    How the work was done

    The new study was carried out by scientists in Germany who tested HQC on a collection of different cell types to figure out why this drug doesn't prevent the virus from infecting humans.

    Their findings clearly show that that HQC can block the coronavirus from infecting kidney cells from the African green monkey. But it does not inhibit the virus in human lung cells – the primary site of infection for the SARS-CoV-2 virus.

    In order for the virus to enter a cell, it can do so by two mechanisms - one, when the SARS-CoV-2 spike protein attaches to the ACE2 receptor and inserts its genetic material into the cell. In the second mechanism, the virus is absorbed into some special compartments in cells called endosomes.

    Depending on the cell type, some, like kidney cells, need an enzyme called cathepsin L for the virus to successfully infect them. In lung cells, however, an enzyme called TMPRSS2 (on the cell surface) is necessary. Cathepsin L requires an acidic environment to function and allow the virus to infect the cell, while TMPRSS2 does not.

    In the green monkey kidney cells, both hydroxychloroquine and chloroquine decrease the acidity, which then disables the cathepsin L enzyme, blocking the virus from infecting the monkey cells. In human lung cells, which have very low levels of cathepsin L enzyme, the virus uses the enzyme TMPRSS2 to enter the cell.

    But because that enzyme is not controlled by acidity, neither HCQ and CQ can block the SARS-CoV-2 from infecting the lungs or stop the virus from replicating.

    Why it matters

    This matters for several reasons. One, much time and money has been spent studying a drug that many scientists said from the very beginning was not going to be effective in killing the virus.

    The second reason is that the studies that have reported antiviral activity for hydroxychloroquine were not in epithelial lung cells. Thus, their results are not relevant to properly studying SARS-CoV-2 infections in humans.

    What's next?

    As scientists proceed with investigating new drugs as well as trying to repurpose old ones, like hydroxychloroquine, it is critical that researchers take the time to think about their study design.

    In short, those of us involved in antiviral drug development should all take a lesson from this study. It is important not only to focus our efforts on pursuing drugs that will directly shut down viral replication, but also to study the virus in the primary site of infection.
    The Conversation


    Katherine Seley-Radtke, Professor of Chemistry and Biochemistry and President-Elect of the International Society for Antiviral Research, University of Maryland, Baltimore County.

    This article is republished from The Conversation under a Creative Commons license. Read the original article.


    这可能是氯喹和羟氯喹对新冠作用有限的原因:不能有效阻止病毒进入肺细胞 (链接)
     

    向问天

    日月神教光明左使
    VIP
    注册
    2012-09-04
    消息
    52,733
    荣誉分数
    9,889
    声望点数
    273
    好像在CFC有更牛逼的专家不服气。

    :evil: :monster:
     

    lindamy

    时代广场舞照跳
    VIP
    注册
    2005-11-23
    消息
    13,832
    荣誉分数
    3,021
    声望点数
    373
    好像在CFC有更牛逼的专家不服气。

    :evil: :monster:
    这药被共和党视为神药,民主党当作毒药。

    有人只看一方面的吹嘘,凡是不同意见一律称为装睡,我收集两方面的证据。起码我看到中国就有几个支持此药的对照试验。初期,轻症,加锌,阿奇霉素,钟南山很早就说过: 这药有效,但非特效。

    效果有限,有明显副作用。
     

    baima123

    新手上路
    注册
    2019-08-29
    消息
    362
    荣誉分数
    204
    声望点数
    43
    这药被共和党视为神药,民主党当作毒药。

    有人只看一方面的吹嘘,凡是不同意见一律称为装睡,我收集两方面的证据。起码我看到中国就有几个支持此药的对照试验。初期,轻症,加锌,阿奇霉素,钟南山很早就说过: 这药有效,但非特效。

    效果有限,有明显副作用。
    这对比。
    有的人会说: 米国民主。每个人(党派)自由发声(真假不管,对自己有利的就是正义的)
    中国专政,居然一个声音一种意见————重症不管用,轻症有一定疗效,有副作用。 :p
     

    PAL

    资深人士
    注册
    2002-08-18
    消息
    1,641
    荣誉分数
    296
    声望点数
    243
    2020神奇之一:药物疗效的政治化,开眼了
     

    livingeverywhere

    一直在被删帖,还被不停的各种限制发言,哈哈,等CFC被联邦调查就好玩了嘛,坐实了中共狗腿的名
    注册
    2008-08-02
    消息
    6,516
    荣誉分数
    692
    声望点数
    223
    WHO早就作为基本药物,会不知道这个治疗疟疾的药的副作用?这不是笑话么?
     

    lindamy

    时代广场舞照跳
    VIP
    注册
    2005-11-23
    消息
    13,832
    荣誉分数
    3,021
    声望点数
    373
    9 min ago
    A renewed focus on hydroxychloroquine wastes time and risks lives, 24 Yale faculty members say
    From CNN's Maggie Fox


    In this photo illustration a pack of Hydroxychloroquine Sulfate medication is held up on March 26 in London.

    In this photo illustration a pack of Hydroxychloroquine Sulfate medication is held up on March 26 in London. John Phillips/Getty Images

    A renewed focus on the potential use of the malarial drug hydroxychloroquine is taking time and resources away from the search for something that actually does work to help coronavirus patients and may end up costing lives, two dozen Yale University researchers said Tuesday.

    Yale cancer epidemiologist Dr. Harvey Risch launched a new round of headlines when he wrote a commentary in Newsweek last month calling for renewed research on hydroxychloroquine as a treatment for coronavirus, despite multiple studies showing it doesn’t help and might harm patients, and decisions by the US Food and Drug Administration, National Institutes of Health, and the World Health Organization to stop further testing.

    The White House, which had promoted the drug, was encouraged to renew its lobbying for the drug, even as coronavirus task force members, including Dr. Anthony Fauci, Dr. Deborah Birx and Adm. Brett Giroir, all said repeatedly the drug does not work and should be dropped.
    “We write with grave concern that too many are being distracted by the ardent advocacy of our Yale colleague, Dr. Harvey Risch, to promote the assertion that hydroxychloroquine (HCQ) when given with antibiotics is effective in treating COVID-19, in particular as an early therapeutic intervention for the disease,” the 24 Yale staffers wrote in an open letter posted on Medium. “As his colleagues, we defend the right of Dr. Risch, a respected cancer epidemiologist, to voice his opinions. But he is not an expert in infectious disease epidemiology and he has not been swayed by the body of scientific evidence from rigorously conducted clinical trials, which refute the plausibility of his belief and arguments."
    The Yale researchers said they all want the same thing: an effective treatment for coronavirus. But they said heavy pursuit of hydroxychloroquine took up resources that could be used elsewhere.

    “The continuing advocacy on behalf of HCQ distracts us from advancing the science on Covid-19 and seeking more effective interventions in a time when more than 1,000 people are dying per day of this disease,” they wrote.
     

    向问天

    日月神教光明左使
    VIP
    注册
    2012-09-04
    消息
    52,733
    荣誉分数
    9,889
    声望点数
    273
    到现在还在争论羟禄溃,说明西方的医疗体系存在严重缺陷。
     
    顶部